Genalyte, a clinical diagnostics company, released clinical abstracts for the Maverick Detection System, which the company claims could produce results more quickly and offer remote testing in the detection of anti-nuclear antibodies for the diagnosis of connective tissue diseases.

“The feasibility of performing multiplex antinuclear antibodies testing on whole blood in a near patient setting in an outpatient clinic,” said Smitha Reddy, MD, medical director of the Arthritis Care and Research Center of San Diego. "There is high correlation between venous blood and finger-stick blood and between positive and negative results on the Maverick and comparative devices."

Testing the Maverick platform on more than 750 patients in rheumatology offices for four months, Genalyte was able to compare the results with conventional labs and their associated patient diagnostic procedures. Results showed the Maverick system could be tested remotely. The blood testing also was on par with previously approved devices, with a high correlation of results between venous draw and finger-stick blood samples.

"Genalyte's goal is to put a rapid and powerful suite of diagnostic tests in every physician's office, and these initial trials illustrate that our team has made significant strides in that direction," said Cary Gunn, MD, Genalyte's founder and CEO.